Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
| Revenue (TTM) | $333.65B |
| Gross Profit (TTM) | $278.04B |
| EBITDA | $181.56B |
| Operating Margin | 40.10% |
| Return on Equity | 58.40% |
| Return on Assets | 19.10% |
| Revenue/Share (TTM) | $75.25 |
| Book Value | $7.42 |
| Price-to-Book | 5.44 |
| Price-to-Sales (TTM) | 0.53 |
| EV/Revenue | 3.849 |
| EV/EBITDA | 7.43 |
| Quarterly Earnings Growth (YoY) | -15.80% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $3.33B |
| Float | $3.16B |
| % Insiders | 0.00% |
| % Institutions | 9.85% |
Volatility is currently expanding
Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis. Projected annualized returns exceed 18% through 2030, underpinned by expanding oral GLP-1 market share and pipeline momentum.
Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.
Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next year's sales and three hurting them.
Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript
Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices fall and a rival closes in.
Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.
Novo Nordisk A/S delivered a strong Q3 with a double beat and raised guidance, signaling a turnaround and renewed growth trajectory. Obesity care, especially the Wegovy pill, is driving revenue growth, offsetting declines in diabetes; international markets outperform the U.S. Margins have rebounded with an adjusted operating margin of 40.1%, and robust cash flow and interest coverage support financial strength.
The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVO and any ticker you trade — then tracks every position and per-strategy win rate.
